Zai Lab Limited Announces Equity Incentive Grants
Zai Lab Limited announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan. The company granted options for 11,800 ADSs to three employees and restricted share units for 22,665 ADSs to six employees. This move is part of their market-competitive approach to incentivize employee performance. Zai Lab is a biopharmaceutical company focusing on oncology, autoimmune disorders, and infectious diseases.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zai Lab Ltd ( (HK:9688) ) has shared an announcement.
Zai Lab Limited announced the grant of share options and restricted share units under its 2024 Equity Incentive Plan. The company granted options to subscribe for 11,800 ADSs to three employees and restricted share units covering 22,665 ADSs to six employees. This move aligns with the company’s customary practice and aims to incentivize employee performance without attaching performance targets or clawback mechanisms, reflecting a market-competitive approach.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative therapies. The company operates within the healthcare industry, with a primary focus on oncology, autoimmune disorders, and infectious diseases.
Average Trading Volume: 13,184,219
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.57B
